ABSTRACT

Systemic sclerosis (SSc) is a rare multisystemic chronic immune-mediated rheumatic disease. Although it is not common, it still has the highest mortality and morbidity rate among the systemic rheumatic diseases. This review aimed to analyze the results of multiple preclinical trials and clinical data about Janus kinase (JAK) inhibitors in SSc treatment and provides a comprehensive overview of JAK inhibitors as a new treatment option in SSc.

Keywords: Systemic sclerosis, JAK inhibitors, tofacitinib, baricitinib, ruxolitinib